eCourse
PARP Inhibition in Ovarian Cancer: Current Evidence
Release Date: February 26, 2021
Expiration Date: February 25, 2022
CE/CME Credit Hours: 1.00
Pharmacology Credit Hours: 1.00
Begin »
program overview
Program Description
Ovarian cancer is a leading cause of cancer deaths among women, with a 5-year survival rate of only 30% in patients with advanced disease—the most common stage at diagnosis. One treatment approach that is improving these sobering odds is frontline maintenance therapy with poly (ADP-ribose) polymerase inhibitors (PARPi's), which improves progression-free survival in women with Stage III-IV ovarian cancer following complete or partial response to frontline platinum-based chemotherapy. This is especially true for women with BRCA mutations or homologous recombination deficiency. In this interactive eCourse, two experts in gynecologic oncology explain key evidence supporting the role of PARP inhibition in frontline maintenance therapy, and use video vignettes to demonstrate the importance of collaborative management by the multidisciplinary team.
Format
Interactive, video-enhanced slide lecture
Learning Objectives
After completing this activity, participants should be better able to:
- Identify current recommendations for molecular testing in ovarian cancer
- Describe evidence for the appropriate use of PARPi's in ovarian cancer
- Implement recommended strategies to monitor adherence and manage adverse events associated with PARPi's
Target Audience
Oncology NPs, PAs, and nurses
Faculty
Bradley Monk, MD
- Professor, Division of Gynecologic Oncology
- Arizona Oncology (US Oncology Network)
- University of Arizona College of Medicine
- Creighton University School of Medicine at St. Joseph's Hospital Medical
- Medical Director, US Oncology Research Network — Gynecologic Program
- Co-Director, GOG-Partners
- Member, Board of Directors, GOG-Foundation
- Phoenix, Arizona
Kimberly J. Halla, MSN, FNP-C
- Family Nurse Practitioner
- Arizona Oncology
- Phoenix, Arizona
Details
Joint Accreditation Statement
In support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
ANCC Credit Designation
Nursing contact hours: 1.00, which includes 1.00 hour of pharmacology credit.
Practicing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. Approval is valid until February 25, 2022. PAs should only claim credit commensurate with the extent of their participation.
PA course advisor: Corinne Williams, PA-C, Northwestern University Feinberg School of Medicine, Chicago, Illinois
IPCE Credit Designation
This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.
This activity is supported by an educational grant from AstraZeneca, GlaxoSmithKline, and Merck & Co.
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.
All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange (PCE) are required to disclose to the audience all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PCE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Ms Halla: speakers bureau: GlaxoSmithKline, Merck.
Dr Monk: consultant: Aravive, Elevar Therapeutics, Gradalis, ImmunoGen, Mersana Therapeutics, Novocure, Pfizer, VBL Therapeutics; consultant/speaker's bureau: Clovis Oncology, Myriad.
Ms Williams: speakers bureau: AstraZeneca.
None of the members of the Planning Committee or PCE staff have any relevant relationships to disclose, except Ms Williams as noted above.
Participants wishing to earn CE/CME credit must:
- View the content in its entirety
- Relate the content material to the learning objectives
- Complete the post-test and evaluation form
Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of at least 67%.
The estimated time to complete this activity is 1.00 hours.
Release date: February 26, 2021
Expiration date: February 25, 2022
For Practicing Clinicians Exchange general information, contact pce@practicingclinicians.com.
© 2021 Practicing Clinicians Exchange. All Rights Reserved. 100920AZ